Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares

 

LUND, Sweden, Nov. 17, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") announced today that Immunovia's Chief Executive Officer, Patrik Dahlen, has acquired Immunovia 15,000 shares for 2.5 MSEK on the open market and his total holding is now 45,000 shares.

For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia

Email: julie.silber@immunovia.com

Tel: +46 7 93 486 277

The information was submitted for publication, through the agency of the contact person set out above, at 17:30 CET on November 17, 2020.

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.

When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.

Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/chief-executive-officer--patrik-dahlen-buys-immunovia-shares,c3238889

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/chief-executive-officer-patrik-dahlen-buys-immunovia-shares-301175081.html

SOURCE Immunovia AB

 
 
Company Codes: Bloomberg:IMMNOV@SS, ISIN:SE0006091997, RICS:IMMNOV.ST, Stockholm:IMMNOV
 

Back to news